{"text": ["Novartis", "completes", "subsequent", "offering", "period", "of", "the", "tender", "offer", "for", "Advanced", "Accelerator", "Applications", "S.A."], "created_at": "2018-02-01 21:06:02"}
{"text": ["Advanced", "Accelerator", "Applications", "Announces", "Completion", "of", "Subsequent", "Offering", "Period", "for", "Novartis", "Tender", "Offer"], "created_at": "2018-02-01 21:05:00"}
{"text": ["Novartis", "Closes", "Subsequent", "Offering", "Period", "Of", "Tender", "Offer", "For", "AAAP"], "created_at": "2018-02-01 19:52:00"}
{"text": ["Novartis", "Closes", "Subsequent", "Offering", "Period", "Of", "Tender", "Offer", "For", "AAAP"], "created_at": "2018-02-01 19:52:00"}
{"text": ["Commentary:", "How", "We", "Can", "Bring", "Health", "Care", "to", "the", "World\u2019s", "Underserved"], "created_at": "2018-02-01 19:00:48"}
{"text": ["Analyzing", "Celgene\u2019s", "Performance", "in", "4Q17"], "created_at": "2018-02-01 18:19:34"}
{"text": ["Roche", "(RHHBY)", "Posts", "Solid", "2017", "Sales", "on", "Tecentriq", "&", "Alecensa"], "created_at": "2018-02-01 17:01:03"}
{"text": ["Roche", "(RHHBY)", "Posts", "Solid", "2017", "Sales", "on", "Tecentriq", "&", "Alecensa"], "created_at": "2018-02-01 17:01:03"}
{"text": ["GSK", "Projects", "Modest", "Long-Term", "Revenue", "Growth", "for", "Vaccines", "Portfolio"], "created_at": "2018-02-01 15:31:14"}
{"text": ["The", "Swiss", "Stock", "Market", "Fell", "On", "Pharma", "Weakness"], "created_at": "2018-02-01 12:17:00"}
{"text": ["The", "Swiss", "Stock", "Market", "Fell", "On", "Pharma", "Weakness"], "created_at": "2018-02-01 12:17:00"}
{"text": ["Stada", "Names", "Sandoz", "Manager", "as", "Fifth", "CEO", "Since", "2016"], "created_at": "2018-02-01 10:14:05"}
